2. Signaling Pathways
  3. Immunology/Inflammation
  4. BCL6
  5. BCL6 Inhibitor

BCL6 Inhibitor

BCL6 Inhibitors (5):

Cat. No. Product Name Effect Purity
  • HY-161138
    WK369
    		Inhibitor 99.89%
    WK369 is a novel BCL6 small molecule inhibitor, which exhibits excellent anti-ovarian cancer bioactivity, induces cell cycle arrest and causes apoptosis. WK369 can directly bind to the BCL6-BTB domain and block the interaction between BCL6 and SMRT, leading to the reactivation of p53, ATR and CDKN1A.
  • HY-164098
    JWZ-7-7-Neg1
    		Inhibitor
    JWZ-7-7-Neg1 is a transcriptional chemical inducers of proximity (TCIP) with negative chemical control. JWZ-7-7-Neg1 reduces the ability to bind to BRD4 or BCL6, so it has less cytotoxicity to DLBCL cells, in compared with JWZ-7-7.
  • HY-P10566
    BCOR(498-514), biotinylated
    		Inhibitor
    BCOR(498-514), biotinylated is the minimal BCL6 binding domain with an KD value of 1.32 µM. BCOR(498-514), biotinylated blocks BCL6-mediated transcriptional repression and kills lymphoma cells.
  • HY-153521
    CCT374705
    		Inhibitor 99.30%
    CCT374705 is an orally active BCL6 inhibitor with potent antiproliferative effects in vitro. CCT374705 effectively inhibits tumor growth in a lymphoma xenograft mouse model.
  • HY-P10543
    SMRT peptide
    		Inhibitor
    SMRT peptide is one of the co-repressors of BCL6 BTB domain interaction. SMRT peptide binds to the BTB domain of BCL6 and enhances the transcriptional repression function of BCL6. SMRT peptide can be used to study protein-protein interactions.